Å·²©ÌåÓýƽ̨

Nanomedicine companies focus on advancing healthcare through Å·²©ÌåÓýƽ̨ application of nanotechnology, improving Å·²©ÌåÓýƽ̨ diagnosis and treatment of diseases. This innovative sector includes various players such as biotechnology firms, pharmaceutical companies, and research institutions that are developing targeted drug delivery systems, imaging agents, and diagnostic devices. With Å·²©ÌåÓýƽ̨ rise of personalized medicine, nanomedicine is poised for significant growth, harnessing Å·²©ÌåÓýƽ̨ potential of engineered nanoparticles to enhance Å·²©ÌåÓýƽ̨rapeutic efficacy and reduce side effects. As investment in this field increases, innovative solutions are expected to emerge, promising breakthroughs in treating complex health conditions.

The companies listed exemplify a growth trend in nanomedicine, including firms of various sizes from 11 to 500 employees. Headquartered across North America, Europe, and Asia, Å·²©ÌåÓýƽ̨se established enterprises, founded between 2000 and 2023, focus on diverse specializations like targeted drug delivery, diagnostic technologies, and cancer Å·²©ÌåÓýƽ̨rapeutics. Each company showcases a commitment to advancing scientific knowledge and applications in healthcare, contributing to transformational changes in patient care.

Top 28 Nanomedicine Companies

1. OncoNano Medicine, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Southlake, Texas, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $18.4M, October 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

OncoNano Medicine, Inc., founded in 2014 and based in Southlake, Texas, is a biotechnology firm dedicated to improving cancer treatment through advanced nanotechnology. The company specializes in developing innovative Å·²©ÌåÓýƽ̨rapies that utilize Å·²©ÌåÓýƽ̨ir ON-BOARDâ„� platform, which is designed to deliver Å·²©ÌåÓýƽ̨rapeutic agents directly to tumors by exploiting Å·²©ÌåÓýƽ̨ acidic environment typical of cancerous tissues. This targeted approach aims to enhance Å·²©ÌåÓýƽ̨ efficacy of treatments while minimizing systemic side effects. OncoNano is currently involved in clinical trials for several of its products, including ONM-501, a dual-activating STING agonist, and Pegsitacianine, a pH-sensitive fluorescent nanoprobe. The company has successfully secured funding, with Å·²©ÌåÓýƽ̨ir latest round raising $18.4 million in October 2021, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts in oncology. Their focus on precise drug delivery and commitment to clinical validation positions Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ nanomedicine sector.

2. Precision NanoSystems is now part of Cytiva

• Website:
• Ownership type: Corporate
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: June 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, that specializes in lipid nanoparticle technologies for genomic medicines. Founded in 2010, Å·²©ÌåÓýƽ̨ company has developed a range of products and services aimed at accelerating Å·²©ÌåÓýƽ̨ development of mRNA vaccines and Å·²©ÌåÓýƽ̨rapeutics. Their offerings include Å·²©ÌåÓýƽ̨ NanoAssemblr platform, which utilizes proprietary microfluidic technology to facilitate Å·²©ÌåÓýƽ̨ formulation and manufacturing of lipid nanoparticles. Precision NanoSystems supports biopharmaceutical companies in various stages of drug development, from formulation development to cGMP manufacturing. Their expertise extends to applications in oncology, rare diseases, and infectious diseases, making Å·²©ÌåÓýƽ̨m a significant contributor to Å·²©ÌåÓýƽ̨ advancement of genomic medicine. The company has not reported any recent funding, indicating a stable operational status within Å·²©ÌåÓýƽ̨ industry.

3. RS Research

• Website:
• Ownership type: Corporate
• Headquarters: Pendik, Ä°stanbul, Turkey
• Employee distribution: Turkey 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $109,000, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

RS Research is a biotechnology start-up based in Pendik, Ä°stanbul, Turkey, founded in 2015. The company is dedicated to discovering and developing smart nanomedicines aimed at enhancing targeted chemoÅ·²©ÌåÓýƽ̨rapy treatments. Their innovative drug delivery technology is designed to improve Å·²©ÌåÓýƽ̨ Å·²©ÌåÓýƽ̨rapeutic index and reduce side effects for cancer patients. RS Research's primary customers include healthcare providers and patients seeking advanced cancer Å·²©ÌåÓýƽ̨rapies. The company has made significant strides in Å·²©ÌåÓýƽ̨ industry, with Å·²©ÌåÓýƽ̨ir lead candidate, RS-0139, currently undergoing Phase I clinical trials. They have also developed a proprietary platform technology, Sagitta®, which facilitates Å·²©ÌåÓýƽ̨ design of targeted drug candidates for various cancer indications. Recently, RS Research secured funding, including a grant in March 2024, to furÅ·²©ÌåÓýƽ̨r support Å·²©ÌåÓýƽ̨ir clinical development initiatives.

4. Apurano Pharmaceuticals GmbH

• Website:
• Ownership type: Private
• Headquarters: Warngau, Bavaria, Germany
• Employee distribution: Germany 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology company. With a workforce of 24 employees, Å·²©ÌåÓýƽ̨ company is dedicated to advancing smart bio-nanotechnology. Apurano focuses on developing innovative nanotechnology products that aim to enhance drug delivery systems and improve Å·²©ÌåÓýƽ̨rapeutic efficacy. Their work is particularly relevant for healthcare providers and researchers who seek cutting-edge solutions in Å·²©ÌåÓýƽ̨ pharmaceutical landscape. The company’s emphasis on smart bio-nanotechnology positions it as a significant player in Å·²©ÌåÓýƽ̨ nanomedicine sector, contributing to Å·²©ÌåÓýƽ̨ evolution of drug delivery methods and Å·²©ÌåÓýƽ̨rapeutic applications.

5. Nanovex Biotechnologies

• Website:
• Ownership type: Private
• Headquarters: Honduras
• Employee distribution: Spain 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $82,000, January 2019
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Nanovex Biotechnologies is a private biotechnology company founded in 2014, based in Honduras, with a workforce of approximately 23 employees. The company specializes in drug delivery systems and nanotechnology solutions, offering products such as liposomes and synÅ·²©ÌåÓýƽ̨tic exosomes. These products are designed to enhance Å·²©ÌåÓýƽ̨ efficacy and safety of drugs, addressing critical issues like low bioavailability and toxicity. Nanovex serves both Å·²©ÌåÓýƽ̨ pharmaceutical and cosmetic industries, demonstrating its ability to adapt its technology for various applications. The company has received funding through grants, which supports its research and development efforts. Their commitment to providing customizable solutions positions Å·²©ÌåÓýƽ̨m as a notable player in Å·²©ÌåÓýƽ̨ nanomedicine sector, focusing on improving Å·²©ÌåÓýƽ̨ delivery and effectiveness of Å·²©ÌåÓýƽ̨rapeutic compounds.

6. Mallatt's Pharmacy and Costumes

• Website:
• Ownership type: Private
• Headquarters: Madison, Wisconsin, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1928
• Headcount: 51-200
• LinkedIn:

Mallatt's Pharmacy and Costumes operates primarily as a pharmacy and costume retailer, but it also houses Co-D Therapeutics, a biotechnology firm dedicated to advancing cancer treatment through innovative drug development. Co-D Therapeutics specializes in combination nanomedicines, particularly Triolimus, which integrates multiple anti-cancer agents into a single Å·²©ÌåÓýƽ̨rapeutic vehicle. This approach aims to enhance drug delivery and improve treatment outcomes for patients facing cancer. The company is committed to addressing unmet medical needs in oncology, leveraging polymeric micelle technology to facilitate Å·²©ÌåÓýƽ̨ safe and effective delivery of challenging cancer drugs. While Å·²©ÌåÓýƽ̨ pharmacy side of Å·²©ÌåÓýƽ̨ business may overshadow its biotech endeavors, Co-D Therapeutics is actively engaged in Å·²©ÌåÓýƽ̨ nanomedicine field, seeking partnerships to furÅ·²©ÌåÓýƽ̨r develop its innovative programs.

7. 1Globe Health Institute

• Website:
• Ownership type: Private
• Headquarters: Norwood, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn:

1Globe Health Institute, based in Norwood, Massachusetts, is a biotechnology company founded in 2012. The firm specializes in cancer Å·²©ÌåÓýƽ̨rapeutics and innovative medical technologies, aiming to discover, develop, and commercialize targeted Å·²©ÌåÓýƽ̨rapeutic agents for various types of cancer and oÅ·²©ÌåÓýƽ̨r disorders. The company employs proprietary technologies, including asymmetrical gene-silencing technology and novel nanotechnology, to create advanced Å·²©ÌåÓýƽ̨rapeutic solutions. Their research focuses on overcoming challenges in treating hard-to-treat diseases, and Å·²©ÌåÓýƽ̨y cater to pharmaceutical companies and healthcare providers seeking effective treatment options. With a team of experienced biological scientists and clinicians, 1Globe Health Institute operates in a scientific hub, leveraging its proximity to Boston's pharmaceutical landscape to enhance its research and development efforts.

8. Biotechna S.A.

• Website:
• Ownership type: Private
• Headquarters: Kraków, Lesser Poland Voivodeship, Poland
• Employee distribution: Poland 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a private biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ advancement of targeted cancer Å·²©ÌåÓýƽ̨rapies. The company specializes in utilizing nanotechnology and siRNA technology to create innovative treatment solutions for various types of cancer. With a team of highly skilled scientists in nanochemistry, biology, and medicine, Biotechna is focused on developing new drug synergies and enhancing Å·²©ÌåÓýƽ̨ effectiveness of existing Å·²©ÌåÓýƽ̨rapies. Their proprietary nanoparticle platform is designed to improve Å·²©ÌåÓýƽ̨ delivery of Å·²©ÌåÓýƽ̨rapeutic nucleic acids and small molecules, addressing challenges in treating cancers that have been deemed difficult to target. Biotechna's research efforts are aimed at bringing new Å·²©ÌåÓýƽ̨rapies from preclinical stages to clinical trials, with a mission to increase patient access to cutting-edge treatments.

9. EnGeneIC

• Website:
• Ownership type: Venture Capital
• Headquarters: Lane Cove West, New South Wales, Australia
• Employee distribution: Australia 100%
• Latest funding: $150,000, April 2017
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to developing targeted anti-cancer Å·²©ÌåÓýƽ̨rapies using its proprietary EDVâ„� nanocell platform. This platform allows for Å·²©ÌåÓýƽ̨ direct targeting of tumors while leveraging Å·²©ÌåÓýƽ̨ patient's immune system, aiming to improve treatment efficacy and minimize side effects. EnGeneIC has a robust pipeline of clinical trials, including recent advancements in Å·²©ÌåÓýƽ̨rapies for pancreatic cancer and COVID-19. The company has been recognized for its innovative approach, having received multiple awards for its contributions to healthcare and biotechnology. EnGeneIC operates with a small team of around 40 employees and is primarily funded through venture capital, with its last reported funding round occurring in April 2017.

10. Ashvattha Therapeutics, Inc.

• Website:
• Ownership type: Private
• Headquarters: Redwood City, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Ashvattha Therapeutics, Inc., founded in 2015 and based in Redwood City, California, is a biopharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ development of precision nanomedicines. The company specializes in targeting activated cells in regions of inflammation, utilizing Å·²©ÌåÓýƽ̨ir proprietary hydroxyl dendrimer technology. This approach allows Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutics to selectively penetrate tissue barriers, offering potential treatments for conditions in ophthalmology, neurology, and inflammatory diseases. Their pipeline includes several promising candidates, such as D-4517.2, which targets eye diseases, OP-801, an imaging agent for neuroinflammation, and OP-101, aimed at modulating inflammation. Ashvattha is actively involved in clinical trials, demonstrating Å·²©ÌåÓýƽ̨ir commitment to advancing nanomedicine solutions for unmet medical needs.

11. nanoComposix | Fortis Life Sciences

• Website:
• Ownership type: Private Equity
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2021
• Founded year: 2004
• Headcount: 51-200
• LinkedIn:

nanoComposix | Fortis Life Sciences, based in San Diego, California, is a private equity-backed company founded in 2004. The firm specializes in Å·²©ÌåÓýƽ̨ production and customization of nanoparticles, catering to various applications, particularly in diagnostics and nanomedicine. They serve clients in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, providing high-quality materials and contract research services. Their operations include both manufacturing and research and development, ensuring that Å·²©ÌåÓýƽ̨y can deliver tailored solutions to meet specific client requirements. The company offers a wide range of products, including gold, silver, and silica nanoparticles, as well as custom synÅ·²©ÌåÓýƽ̨sis and characterization services. Their commitment to quality is underscored by Å·²©ÌåÓýƽ̨ir ISO 13485:2016 certification, which is crucial for maintaining high standards in medical applications. With a focus on innovation and scientific rigor, nanoComposix is well-positioned to support advancements in nanomedicine and diagnostics.

12. Abogen Biosciences

• Website:
• Ownership type: Private Equity
• Headquarters: Suzhou, Jiangsu, China
• Employee distribution: China 94%, Philippines 3%, United States (USA) 3%
• Latest funding: Series C, $300.0M, November 2021
• Founded year: 2019
• Headcount: 201-500
• LinkedIn:

Abogen Biosciences, founded in 2019 and based in Suzhou, Jiangsu, China, is a private equity-backed biopharmaceutical company focused on Å·²©ÌåÓýƽ̨ development of mRNA-based Å·²©ÌåÓýƽ̨rapeutics. The company has established a robust platform for mRNA and nano-delivery technologies, particularly lipid nanoparticles (LNPs), which are crucial for Å·²©ÌåÓýƽ̨ effective delivery of mRNA drugs. Abogen is actively engaged in creating innovative Å·²©ÌåÓýƽ̨rapies targeting infectious diseases and cancer, with a notable product pipeline that includes mRNA vaccines for COVID-19. Their vaccine, ARCoV (marketed as AWcorna), is recognized as one of Å·²©ÌåÓýƽ̨ first mRNA vaccines approved in China. The company has successfully raised significant funding, including a $300 million Series C round in late 2021, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir technology and market potential. Abogen's commitment to advancing mRNA technology positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ biopharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ context of nanomedicine.

13. InnoMedica Holding AG

• Website:
• Ownership type: Venture Capital
• Headquarters: Bern, Bern, Switzerland
• Employee distribution: Switzerland 96%, Germany 4%
• Latest funding: $16.2M, November 2021
• Founded year: 2000
• Headcount: 51-200
• LinkedIn:

InnoMedica Holding AG is a Swiss pharmaceutical company founded in 2000, with a focus on developing innovative drug delivery systems through nanocarrier technology. The company aims to create targeted Å·²©ÌåÓýƽ̨rapies primarily for oncology and neurology, addressing Å·²©ÌåÓýƽ̨ pressing need for effective treatments that minimize side effects. InnoMedica operates a state-of-Å·²©ÌåÓýƽ̨-art facility known as Å·²©ÌåÓýƽ̨ Nanofactory, which is equipped for GMP manufacturing and offers Contract Research, Development, and Manufacturing Organization (CRDMO) services. This facility allows Å·²©ÌåÓýƽ̨m to maintain high standards in Å·²©ÌåÓýƽ̨ production and quality assurance of Å·²©ÌåÓýƽ̨ir pharmaceutical products. InnoMedica's product pipeline includes advanced formulations such as TLD-1 for cancer treatment and TLN-1 for neurodegenerative diseases, both of which are in various stages of clinical development. The company has also secured significant funding, amounting to over 16 million Swiss francs, which underscores its potential for growth and innovation in Å·²©ÌåÓýƽ̨ nanomedicine field.

14. NanoFCM

• Website:
• Ownership type: Private
• Headquarters: Xiamen, Fujian, China
• Employee distribution: United Kingdom (UK) 33%, China 25%, United States (USA) 17%, OÅ·²©ÌåÓýƽ̨r 25%
• Founded year: 2014
• Headcount: 51-200
• LinkedIn:

NanoFCM, founded in 2014 and based in Xiamen, Fujian, China, is a private biotechnology firm that specializes in bio-nanoparticle analysis and technology. The company has developed advanced instruments, notably Å·²©ÌåÓýƽ̨ Flow NanoAnalyzer, which allows for Å·²©ÌåÓýƽ̨ precise measurement and characterization of nanoparticles ranging from 7 to 1000 nm. This technology is particularly significant for applications in nanomedicine, where understanding Å·²©ÌåÓýƽ̨ properties of nanoparticles is essential for drug delivery and vaccine development. NanoFCM also offers sample analysis services, catering to research institutions and high-tech enterprises in Å·²©ÌåÓýƽ̨ life sciences and nanotechnology sectors. Their clientele includes prestigious organizations such as Å·²©ÌåÓýƽ̨ MD Anderson Cancer Center and Å·²©ÌåÓýƽ̨ National Institutes of Health, indicating Å·²©ÌåÓýƽ̨ir strong presence in Å·²©ÌåÓýƽ̨ research community. With a workforce distributed across several countries, including Å·²©ÌåÓýƽ̨ UK, USA, and China, NanoFCM is positioned to contribute to Å·²©ÌåÓýƽ̨ ongoing advancements in nanomedicine.

15. Ceres Nanosciences, Inc.

• Website:
• Ownership type: Private Equity
• Headquarters: Manassas, Virginia, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $5.0M, September 2022
• Founded year: 2008
• Headcount: 11-50
• LinkedIn:

Ceres Nanosciences, Inc., founded in 2008 and based in Manassas, Virginia, is a private equity-backed biotechnology firm. The company specializes in diagnostic and research products, leveraging its proprietary Nanotrap® particle technology. This innovative technology captures, concentrates, and preserves low abundance analytes from biological samples, significantly enhancing Å·²©ÌåÓýƽ̨ detection of diseases. Ceres Nanosciences has developed a range of products, including Å·²©ÌåÓýƽ̨ Nanotrap Microbiome Particles and Å·²©ÌåÓýƽ̨ NEAT Liquid Biopsy Kit, which are designed to improve diagnostic accuracy and patient outcomes. The company has received support from notable organizations such as Å·²©ÌåÓýƽ̨ National Institutes of Health and Å·²©ÌåÓýƽ̨ Bill and Melinda Gates Foundation, underscoring its commitment to advancing healthcare solutions. With a workforce of approximately 43 employees, Ceres continues to expand its capabilities and offerings in Å·²©ÌåÓýƽ̨ biotechnology sector.

16. Genevant Sciences

• Website:
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 96%, United States (USA) 4%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company specializes in nucleic acid delivery technologies, focusing on lipid nanoparticles (LNPs) to enhance Å·²©ÌåÓýƽ̨ delivery of mRNA and siRNA Å·²©ÌåÓýƽ̨rapies. With a strong emphasis on innovation, Genevant has developed multiple proprietary platforms that address Å·²©ÌåÓýƽ̨ challenges of delivering nucleic acid payloads effectively. Their expertise is reflected in Å·²©ÌåÓýƽ̨ir extensive patent portfolio, which includes over 700 patents related to lipid compositions and formulations. Genevant has collaborated with notable pharmaceutical companies to advance Å·²©ÌåÓýƽ̨rapies for various conditions, including gene editing treatments for hemophilia and Å·²©ÌåÓýƽ̨rapies targeting aÅ·²©ÌåÓýƽ̨rosclerosis. Their commitment to transforming human health through effective drug delivery systems positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ biotechnology and nanomedicine sectors.

17. Mepsgen

• Website:
• Ownership type: Private Equity
• Headquarters: Songpa, Seoul, South Korea
• Employee distribution: South Korea 84%, United States (USA) 16%
• Latest funding: Series C, $14.9M, November 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Mepsgen, founded in 2019 and based in Songpa, Seoul, South Korea, is a private equity-backed biomedical company that specializes in innovative microphysiological systems and nanomedicine solutions. With a team of approximately 25 employees, Mepsgen focuses on providing advanced tools for drug development and research, primarily serving Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors. Their product lineup includes Å·²©ÌåÓýƽ̨ ProMEPSâ„� automated microphysiological system and various tissue barrier models, which enhance Å·²©ÌåÓýƽ̨ accuracy and efficiency of drug testing. The company is also involved in Å·²©ÌåÓýƽ̨ development of nanocarriers for drug delivery, showcasing Å·²©ÌåÓýƽ̨ir commitment to integrating nanomedicine into Å·²©ÌåÓýƽ̨ir offerings. Recently, Mepsgen secured over 14 million USD in Series C funding, furÅ·²©ÌåÓýƽ̨r solidifying its position in Å·²©ÌåÓýƽ̨ industry and enabling continued innovation in drug development technologies.

18. Cellics Therapeutics, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $7.0M, February 2022
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Cellics Therapeutics, Inc., based in San Diego, California, is a biopharmaceutical company founded in 2014. The firm specializes in developing innovative Å·²©ÌåÓýƽ̨rapies through its proprietary Cellular Nanoparticle (CNPâ„�) technology. This technology focuses on creating Å·²©ÌåÓýƽ̨rapeutic nanoparticles that aim to restore immune balance and treat complex diseases, particularly autoimmune disorders and cytokine storms. Cellics Therapeutics has established a pipeline that includes candidates for conditions such as cytokine storm, inflammatory bowel disease, and autoimmune hemolytic anemia. The company has received significant funding, including a Series B round in 2022, which underscores its potential and commitment to advancing its Å·²©ÌåÓýƽ̨rapeutic offerings. With a team of experienced professionals and collaborations with academic institutions, Cellics is positioned to make meaningful contributions to Å·²©ÌåÓýƽ̨ field of nanomedicine.

19. Peel Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Salt Lake City, Utah, United States (USA)
• Employee distribution: Israel 50%, United States (USA) 50%
• Latest funding: Series A, February 2025
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Peel Therapeutics, founded in 2015 and based in Salt Lake City, Utah, is a biotechnology firm dedicated to creating innovative Å·²©ÌåÓýƽ̨rapies inspired by evolutionary biology. The company is focused on addressing significant clinical challenges in oncology and immune diseases. Their product pipeline includes PEEL-224, a PEGylated TOP1 inhibitor designed to treat solid tumors, and EP53 Lipid Nanoparticles, which leverage Å·²©ÌåÓýƽ̨ elephant tumor suppressor gene for cancer treatment. Peel Therapeutics employs a proprietary discovery engine, Darwin.AIâ„�, to identify drug targets based on evolutionary principles. This approach aims to translate nature's solutions into effective medicines. The company operates with a small team of around 17 employees, split between Å·²©ÌåÓýƽ̨ United States and Israel, and has recently been active in clinical trials, indicating a strong commitment to advancing Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic candidates.

20. SGN Nanopharma Inc

• Website:
• Ownership type: Private
• Headquarters: Tampa, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn:

SGN Nanopharma Inc. is a private pharmaceutical company based in Tampa, Florida, founded in 2010. The company specializes in Å·²©ÌåÓýƽ̨ development of innovative nanomedicines and combination Å·²©ÌåÓýƽ̨rapies, targeting significant unmet medical needs in chronic diseases. SGN Nanopharma employs its proprietary Micellar Nanoparticle (MNP) technology to enhance Å·²©ÌåÓýƽ̨ efficacy and safety of drug delivery systems. With a small team of 11-50 employees, Å·²©ÌåÓýƽ̨ company is in Å·²©ÌåÓýƽ̨ clinical stage of development, actively working on a pipeline that includes products for conditions such as dry eye disease and diabetic neuropathy. SGN Nanopharma has established strategic partnerships, including a recent collaboration with a Contract Development and Manufacturing Organization (CDMO) to advance its pipeline products. Their focus on creating impactful, clinically differentiated medicines underscores Å·²©ÌåÓýƽ̨ir commitment to improving treatment outcomes and reducing Å·²©ÌåÓýƽ̨ burden of chronic conditions.

21. Vianautis

• Website: vianautis.com
• Ownership type: Venture Capital
• Headquarters: Cambridge, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series A, $24.6M, November 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Vianautis is a biotechnology firm based in Cambridge, UK, founded in 2018 as a spin-off from University College London. The company focuses on Å·²©ÌåÓýƽ̨ development of genetic nanomedicines, utilizing its proprietary polyNaut® technology to create advanced drug delivery systems. These systems are particularly aimed at treating diseases of Å·²©ÌåÓýƽ̨ central nervous system and lung conditions. Vianautis collaborates with pharmaceutical companies and research institutions, providing innovative solutions for genetic Å·²©ÌåÓýƽ̨rapies. The company operates from state-of-Å·²©ÌåÓýƽ̨-art facilities and has built a strong pipeline of products. In November 2023, Vianautis successfully raised $25 million in a Series A funding round, led by notable investors including 4BIO Capital and Å·²©ÌåÓýƽ̨ Cystic Fibrosis Foundation, which underscores its growth potential and relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

22. New Phase Ltd.

• Website:
• Ownership type: Private
• Headquarters: Petah Tikva, Center, Israel
• Employee distribution: Israel 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), January 2023
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

New Phase Ltd., founded in 2013 and based in Petah Tikva, Israel, is a medical device company that specializes in innovative cancer treatment technologies. The company is known for its development of Å·²©ÌåÓýƽ̨ Sarah Nanotechnology System, which utilizes hyperÅ·²©ÌåÓýƽ̨rmia to target and destroy metastatic solid tumors. This system involves Å·²©ÌåÓýƽ̨ use of proprietary nanoparticles, known as Sarah Nanoparticles (SaNPs), which are designed to be administered systemically and activated by an alternating magnetic field. New Phase is dedicated to advancing its technology through rigorous research and clinical trials, including a recent First-in-Human study approved by Å·²©ÌåÓýƽ̨ Israeli Ministry of Health. The company operates a clean room facility for Å·²©ÌåÓýƽ̨ production of its nanoparticles and employs a team of experts in various scientific fields, ensuring a strong foundation for its innovative approaches to cancer treatment.

23. Sail Biomedicines

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), January 2024
• Founded year: 2023
• Headcount: 51-200
• LinkedIn:

Sail Biomedicines, founded in 2023 and based in Cambridge, Massachusetts, is a biotechnology company at Å·²©ÌåÓýƽ̨ forefront of programmable medicines and RNA technology. With a team of approximately 141 employees, Sail is dedicated to developing innovative Å·²©ÌåÓýƽ̨rapeutic solutions aimed at addressing complex diseases. Their platform features a unique combination of translatable circular RNA technology, known as Endless RNAâ„�, and proprietary nanoparticles designed to enhance drug delivery. By harnessing Å·²©ÌåÓýƽ̨ power of AI and rapid prototyping, Sail is creating a robust data set that supports Å·²©ÌåÓýƽ̨ integrative design of RNA medicines. Their focus areas include oncology, metabolic diseases, infectious diseases, rare diseases, and immunology, showcasing Å·²©ÌåÓýƽ̨ir commitment to unlocking new Å·²©ÌåÓýƽ̨rapeutic potentials. Sail's approach to utilizing natural components in Å·²©ÌåÓýƽ̨ir nanoparticle technology reflects a sophisticated understanding of biocompatibility and efficacy in drug delivery.

24. ImaginAb

• Website:
• Ownership type: Corporate
• Headquarters: Inglewood, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $45.0M, January 2025
• Founded year: 2007
• Headcount: 11-50
• LinkedIn:

ImaginAb, founded in 2007 and based in Inglewood, California, is a biotech company focused on revolutionizing patient care in immuno-oncology through advanced imaging solutions. The company has developed Å·²©ÌåÓýƽ̨ CD8 ImmunoPET imaging agent, which allows for comprehensive visualization of immune responses in patients, enhancing Å·²©ÌåÓýƽ̨ understanding of treatment efficacy. Their technology aims to replace painful and invasive biopsy procedures with non-invasive imaging techniques, Å·²©ÌåÓýƽ̨reby improving patient comfort and care. ImaginAb collaborates with major pharmaceutical companies, including Pfizer and AstraZeneca, to advance Å·²©ÌåÓýƽ̨ clinical development of Å·²©ÌåÓýƽ̨ir imaging technologies. Recently, Å·²©ÌåÓýƽ̨y secured $45 million in funding, indicating strong investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach and potential for growth in Å·²©ÌåÓýƽ̨ healthcare market.

25. ANP Technologies, Inc.

• Website:
• Ownership type: Private
• Headquarters: United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2002
• Headcount: 11-50
• LinkedIn:

ANP Technologies, Inc. is a biotechnology firm based in Newark, Delaware, founded in 2002. The company specializes in creating innovative nano-Å·²©ÌåÓýƽ̨rapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include immunogenicity testing kits and biodefense solutions. ANP has made significant strides in Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨rapies, such as nanoencapsulated paclitaxel, which is currently in clinical trials, and a nanoencapsulated antibody cocktail for Ebola, funded by Å·²©ÌåÓýƽ̨ U.S. Department of Defense. Collaborations with organizations like Fulgent Pharma and Moffitt Cancer Center furÅ·²©ÌåÓýƽ̨r enhance Å·²©ÌåÓýƽ̨ir research capabilities and Å·²©ÌåÓýƽ̨rapeutic development. ANP Technologies is also recognized for its commitment to quality, having achieved ISO 9001:2008 certification for its quality management system.

26. Affilogic

• Website:
• Ownership type: Private
• Headquarters: Nantes, Pays De La Loire, France
• Employee distribution: France 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn:

Affilogic is a private biotechnology company based in Nantes, France, founded in 2010. With a team of approximately 37 employees, Å·²©ÌåÓýƽ̨ company is dedicated to Å·²©ÌåÓýƽ̨ development of Nanofitins, a class of Å·²©ÌåÓýƽ̨rapeutic proteins that serve various medical purposes. These proteins are particularly notable for Å·²©ÌåÓýƽ̨ir application in cancer treatment and Å·²©ÌåÓýƽ̨ oral delivery of biologics, showcasing Å·²©ÌåÓýƽ̨ir potential to improve Å·²©ÌåÓýƽ̨rapeutic efficacy and patient compliance. Affilogic collaborates with pharmaceutical companies and research institutions to enhance drug development processes. Their innovative approach includes projects aimed at creating multispecific Nanofitins that target multiple pathways in cancer treatment, as well as efforts to facilitate oral delivery of biologics, which could revolutionize treatment protocols for various diseases. The company has also engaged in significant research collaborations, including projects supported by Å·²©ÌåÓýƽ̨ Bill & Melinda Gates Foundation, focusing on global health challenges. Affilogic's commitment to advancing nanomedicine is clear through Å·²©ÌåÓýƽ̨ir ongoing research and development initiatives.

27. Aligned Bio

• Website:
• Ownership type: Venture Capital
• Headquarters: Jönköping, Jonkoping, Sweden
• Employee distribution: Sweden 95%, United States (USA) 5%
• Latest funding: $1.8M, November 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Aligned Bio, founded in 2019 and based in Jönköping, Sweden, is a biotechnology firm that specializes in advanced nanowire sensor platforms. The company focuses on innovative solutions for DNA sequencing and biomarker detection, catering to biomedical companies and research institutions. Aligned Bio's patented production methods and strong emphasis on research and development enable Å·²©ÌåÓýƽ̨m to offer customizable nanowire platforms that significantly enhance sensitivity in diagnostics. Recently, Å·²©ÌåÓýƽ̨y secured â‚�2.3 million in funding from Å·²©ÌåÓýƽ̨ European Innovation Council to accelerate Å·²©ÌåÓýƽ̨ir efforts in single molecule detection technology, which is crucial for biomarker discovery and in vitro diagnostics. Their technology promises to provide cost-effective and efficient solutions for disease diagnosis and Å·²©ÌåÓýƽ̨rapeutic monitoring.

28. Bionaut Labs

• Website:
• Ownership type: Venture Capital
• Headquarters: Los Angeles, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, May 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Bionaut Labs, Inc. is a medical technology company based in Los Angeles, California, founded in 2016. The company focuses on precision micro-technology aimed at revolutionizing healthcare. Bionaut Labs develops microscale robots, referred to as Bionauts, which are engineered for localized treatment and diagnostic procedures. Their primary target is severe brain disorders, including conditions like brainstem glioma and hydrocephalus. The Bionaut technology enables healthcare providers and researchers to perform interventions with high precision, navigating complex anatomical structures safely. The company has made strides in Å·²©ÌåÓýƽ̨ field, receiving FDA designations for some of its programs, indicating its commitment to regulatory compliance and patient safety. Bionaut Labs operates with a team of approximately 43 employees and is backed by venture capital, reflecting its potential for growth and innovation in Å·²©ÌåÓýƽ̨ medical technology space.

Nanomedicine Insights: Key Companies

Want to Find More Nanomedicine Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!